BeOne Medicines Ltd
229 hedge funds and large institutions have $8.07B invested in BeOne Medicines Ltd in 2024 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 79 increasing their positions, 78 reducing their positions, and 32 closing their positions.
20% more call options, than puts
Call options by funds: $27.1M | Put options by funds: $22.6M
13% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 32
1% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 78
0% more funds holding
Funds holding: 228 → 229 (+1)
2.89% less ownership
Funds ownership: 43.94% → 41.05% (-2.9%)
40% less funds holding in top 10
Funds holding in top 10: 10 → 6 (-4)
49% less capital inflows, than outflows
Capital inflows: $642M | Capital outflows: $1.25B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$115M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$84.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$55.2M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$49.6M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$48.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$280M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$212M |
| 3 |
Temasek Holdings
Singapore
|
-$176M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$131M |
| 5 |
Capital International Investors
Los Angeles,
California
|
-$64.9M |
ONC Hedge Fund Activity: Q4 2024 in Review
229 of the 7,614 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines Ltd (ONC) for Q4 2024, worth a combined $8.07B — down 23% from $10.4B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new ONC positions and 32 closed out — a net gain of 4 holders — while 79 added to existing stakes and 78 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $115M. The largest seller was HHLR Advisors, cutting an estimated $280M.
- 229 institutional investors held BeOne Medicines Ltd (ONC) as of Q4 2024, up from 228 in Q3 2024.
- Funds reported $8.07B of BeOne Medicines Ltd stock for Q4 2024, down 23% quarter-over-quarter.
- 36 funds opened new BeOne Medicines Ltd positions in Q4 2024 and 32 closed out, a net change of +4 holders.
- The largest BeOne Medicines Ltd buyer in Q4 2024 was Morgan Stanley, an estimated $115M added.
- The largest BeOne Medicines Ltd seller in Q4 2024 was HHLR Advisors, an estimated $280M sold.
Based on aggregated 13F filings for Q4 2024.